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Although Helicobacter pylori cause gastric cancer, cancer develops in a fraction of H. pylori 
infected patients. Based on the notion that polymorphisms in the H. pylori vacuolating 
cytotoxin gene might be a determinant of clinical outcome, Abdi et al. used meta-analysis to 
examine the association between vacA gene subtypes and the risk of developing atrophic 
gastritis, intestinal metaplasia or gastric cancer (1).
H. pylori infection causes gastric mucosal inflammation which underlies the development of 
peptic ulcer disease and gastric cancer (2). The outcome of any H. pylori infection reflects 
complex interactions between the host, the bacterium and the environment. These 
interactions are evident clinically as marked geographic variation in the prevalence of H. 
pylori-related diseases (3).
The Abdi et al. meta-analysis focuses on one putative H. pylori virulence factor, vacA, the 
vacuolating cytotoxin. More than two decade ago, H. pylori were noted to differ in terms of 
ability to produce vacuolating cytotoxicity in vitro in cultured cells (4). The phenomena 
were subsequently related to the signal (s) and the middle (m) regions of the vacA gene (4). 
Changes in the signal peptide led in a shortened N-terminal portion and an attenuation of 
vacuolation ability. The most active cytotoxin was termed the s1 allele and the less active 
form, s2 allele. The m region of the gene encodes a vacA-to-host cell binding site; the m1 
varient is more effective in binding than the m2 form. Different combinations resulted in 
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different patterns of cytotoxicity: s1m1 strains produce the greatest level of cytotoxicity, 
s1m2 strains do not consistently induce vacuolation, and s2m2 strains are not cytotoxic (4).
The presence of marked geographic variation in the prevalence of vacA genotypes led to 
studies to test whether vacA genotyping might be usefully clinically. Abdi et al. meta-
analysis included 33 studies with 1,446 cases and 2,697 controls and included European, 
Asian and American populations (1). The authors report that the vacA s1 genotype was 
associated with the risk of atrophic gastritis, intestinal metaplasia and gastric cancer [i.e., 
relative risk (RR) =1.116, 95% CI, 1.019–1.222; RR =1.418, 95% CI, 1.035–1.942; and RR 
=1.333, 95% CI, 1.115–1.593, respectively]. The vacA m1 genotype was associated with 
intestinal metaplasia and gastric cancer, but failed to statistically influence the risk of 
atrophic gastritis (RR =1.571, 95% CI, 1.247–1.980 and RR =1.431, 95% CI, 1.180–1.735, 
respectively). Here, we examine whether the association is a determinant of clinical outcome 
(i.e., causative) and whether vacA genotyping has clinical utility.
In 1965, Bradford Hill formulated nine criteria to distinguish simple association from 
causation (5) (Table 1). We use those criteria to evaluate the vacA associations.
Strength
strong associations with a large increase in RR measured by the incidence (or prevalence) of 
the condition among the exposed relative to those unexposed are more likely to be causative 
than weak associations (e.g., the association of death from lung cancer and cigarette 
smoking is 20 times greater than for nonsmokers) (5,6). Although there are no value that 
clearly separates “strong” from “moderate” or “weak” associations, RR values below three 
are considered moderate or weak (7). The Abdi et al. meta-analysis (1) reported relatively 
weak associations (i.e., RR's below 1.5) for both s1 and m1 and for the combination of 
s1m1.
Consistency
causal association (repeatability) should be consistent in different populations, places and 
times (5). Fifteen studies in the meta-analysis (1) confirmed the association of the s1m1 
genotype with an increased risk for gastric cancer, however studies from Belgian and India 
only confirmed an association with vacA s1 but not with m1 (8,9). In Thailand (10), s, m or 
s, m, combination showed no statistically significant association with clinical outcome.
Specificity
causation is more certain when the association is limited to specific workers, anatomic sites, 
and type of disease (5). For example, an exposure that gives rise to a single outcome with no 
other explanation is likely specific (6). H. pylori related diseases are strongly influenced by 
environmental factor and this criterion is not applicable.
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Temporality
temporality relates to exposure and outcome (i.e., the exposure must precede the outcome) 
(5). The temporality criteria is clear for H. pylori as a type I carcinogen (2).
Biologic gradient
biological gradient relates to a dose-response effect (5) (i.e., risk of cancer with an number 
of cigarettes smoked) (6). With vacA one might consider the association between degree of 
cytotoxicity and outcome. Comparison of area with high prevalence of s1m1 strains and 
cancer incidence fails to show either a strong or a consistent correlation. For example, s1m1 
strains are common in China, Japan and Korea where gastric cancer is common (3). They are 
also common in India, Thailand, Bangladesh and Pakistan, sites where gastric cancer is rare. 
For example, in Taiwan vacA m2 strains are present in 87.4% (11) and the ASR of gastric 
cancer is considered high (i.e., 17 cases/100,000 population/year) (12).
Plausibility
causation requires the presence of a biological plausible mechanism that links cause and 
effect (5). To date no convincing mechanism has been described that can link vacA to a 
particular H. pylori-related disease outcome.
Coherence
causality suggest the cause and effect interpretation should not seriously conflict with the 
generally known of natural history and biology of disease (5,6). The lack of a biologically 
plausible mechanism does not allow this factor to be tested.
Experiment
in vitro studies suggest that vacA-induced vacuolation can disrupt protein trafficking 
pathways to and from the plasma membrane and thus influence various cell capacities (13). 
However, the physiological role of vacuolation in vitro remains unclear and animal 
experiments have failed to confirm a vacA-gastric cancer association (14). Experiments 
using gnotobiotic piglets failed to confirm a role of vacA in bacterial colonization, epithelial 
vacuolation or clinical outcome (15). Although vacA mutants colonized less well than their 
wild type vacA counterparts, his loss of vacA did not cause any apparent disadvantage (16). 
A study of the interaction between H. pylori and human T84 epithelial cell polarized 
monolayers using 43,000 element-spotted human cDNA microarrays, failed to detect any 
gene was specifically related with the presence of the vacA gene (17).
Analogy
analogy means the effect of similar factors may be considered. The presence of the s1 vacA 
genotype is strongly associated with the presence other virulence genes particularly the cag 
pathogenicity island, oipA, and babA. Both CagA and OipA are directly associated with the 
production of mucosal inflammation which underlies both gastric cancer and peptic ulcer 
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disease (2). Most likely, the associations ascribed to vacA genotypes reflect the presence of 
these other virulence factors (i.e., CagA, OipA, BabA positive) especially the 
proinflammatory virulence factors, CagA and OipA.
Summary
Gastric cancer is a multifactorial disease related to longs-tanding gastric mucosal 
inflammation enhanced by H. pylori-specific factors that result in genetic instability (2). 
Studies attempting to link individual putative H. pylori virulence factors to specific disease 
outcome while ignoring the presence of other factors (e.g., CagA) are likely to produce 
spurious findings. The outcome of an H. pylori infection reflects intimate interactions 
between the bacteria, the host and the environment. Changes in the environment (e.g., diet) 
can result in a marked change in disease prevalence (e.g., rapid fall in gastric cancer 
incidence). Such that any factor can potentially either enhance or reduce the risk of a 
particular clinical outcome of H. pylori related disease. Disease association studies have 
used an expanding group of vacA gene polymorphisms that include the i (intermediate), the 
d (which refers to a deletion, d, located between the i and m regions), and the c genotypes (a 
polymorphic site in the three end region of vacA) (10). The original predictions made for the 
s, m, and i regions failed as disease determinants in East Asian and Southeast Asian 
countries where gastric cancer is a major clinical problem (18). Predictions for d genotype (a 
deletion, d, located between the i and m regions) base on western countries, failed in East 
Asia (19). Overall, vacA genotyping has generally failed as a consistent and reliable marker 
of risk and cannot be recommended.
Early in H. pylori history, it was suggested that the presence of CagA might serve as a 
biomarker to identify those at highest risk (3). The Maastricht Consensus III conference (20) 
reviewed the role of biomarkers for clinical use in H. pylori and stated “The detection of H 
pylori pathogenic factors and the study of host genetic polymorphisms is currently not 
recommended in the management of H pylori infection”. This recommendation was based 
on failure of identification of such facts to “allow a reliable prediction of the outcome at an 
individual level”. The fact that no H. pylori type has been discovered that does not carry a 
significant risk of development of gastric cancer and peptic ulcer has continued to confirm 
that recommendation. vacA genotype differences most likely reflect genetic drift in 
populations and thus describe the population and it diseases rather than playing a causative 
role. In particular vacA genotyping studies are often surrogates for the presence of other 
virulence factors especially, CagA.
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Table 1
Hill's nine criteria for causation
Strength of association
Consistency
Specificity
Temporality
Biologic gradient
Plausibility
Coherence
Experiment
Analogy
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